(A61K31/495)

Heterocyclic compounds useful as pdk1 inhibitors // 2615130
FIELD: chemistry.SUBSTANCE: present invention relates to novel compounds of general formulae II, III, IV and V, where values of radicals are given in description, or pharmaceutically acceptable salts thereof, which can be used as PDK1 inhibitors.EFFECT: present invention also relates to pharmaceutical compositions based thereon and to methods of treating cancer, mediated by protein kinase PDK1.32 cl, 2 tbl, 445 ex

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex
Composition based on r(-)-praziquantel for treating and preventing helminthiasis in warm-blooded animals // 2613490
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and can be used for treating and preventing helminthiasis in warm-blooded animals, including agricultural and domestic animals, in particular cats and dogs. For this anthelminthic composition is proposed containing as an active agent combination of praziquantel enantiomer (R-praziquantel, R-PZQ), presented in the form of complex with beta-cyclodextrin, and pyrantel pamoat, as well as water and vegetable oil, neutral filler and auxiliary additives, particularly additive with hepatoprotective and GIT microflora recovering action in following proportions (wt%): R-praziquantel 0.1–0.5, pyrantel pamoat 1.0–3.0, beta-cyclodextrin 1.5–5.0, fillers and auxiliary additives 1.2–5.3, vegetable oil 4.0–22.0, water – rest. Proposed water-oil suspension is characterized by wide spectrum of action, storage stability, ease of use, texture and taste, acceptable for animals, and differs from known analogues in higher efficacy of cystocidal action, achieved due to possibility of 2-5-fold reduction of effective dose of R(-)-praziquantel in comparison with conventionally used racemic mixture.EFFECT: invention provides improved consumption by animals, including any kinds of dogs, kittens and puppies, as well as aged and/or debilitated animals.6 cl, 9 tbl, 5 ex
ethod for production of antiparasitic long acting preparation for animals // 2611387
FIELD: veterinary medicine.SUBSTANCE: praziquantel, ivermectin, copolymer of lactic and glycolic acids are mixed with a solvent with the following ingredient ratio (in wt %): praziquantel - 1.0-15.0, ivermectin - 0.5-8.0, copolymer of lactic and glycolic acids - 6.0-16.5, solvent - the rest. At that,praziquantel and ivermectin are the first to be dissolved in the solvent. The solution is then purged with argon or nitrogen and placed in an ultrasonic bath. The mixture is kept in the ultrasonic bath for 50-60 minutes till complete dissolution of the components. Then the copolymer of lactic and glycolic acids is added. For complete copolymer dilution, the obtained mixture is kept for 4-5 hours with occasional stirring at the rotation speed of 1600-2000 rpm. Then, the resulting solution is subjected to sterile filtration, dispensed into vials and sealed.EFFECT: method can reduce loss of active ingredients during manufacture and provide a harmless, non-toxic, sterile and effective long-acting drug for treating animals against a wide range of parasitic infections.5 cl, 8 ex

Lysin-specific demethylase-1 inhibitors and use thereof // 2602814
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to a heterocyclic compound of general formula (I), where (A) denotes phenyl or pyridyl; each (A′), if present, is independently selected from a group consisting of phenyl, phenylC1-C10alkoxy group, phenylC1-C-10alkyl, phenyloxy group and halogen, where each (A′) contains 0, 1, 2 or 3 substitutes independently selected from a group, including halogen, halogenC1-C-10alkyl, phenyl, C1-C10alkyl and C1-C10alkoxy group; X equals 0, 1 or 2; (B) denotes cyclopropyl ring, where (A) and (Z) are covalently bonded to different carbon atoms in (B); (Z) denotes -NH-; (L) is selected from -CH2CH2-, -CH2CH2CH2- and -CH2CH2CH2CH2-; and (D) is selected from -N(-R1)-R2, -O-R3 and -S-R3, where R1 and R2 are bonded to each other, and together with a nitrogen atom to which R1 and R2 are bonded, form a 5- or 6-member heterocyclic ring, where said heterocyclic ring contains 0, 1 or 2 substitutes, independently selected from a group comprising -NH2, -NH(C1-C6-alkyl), -N(C1-C6-alkyl)(C1-C6-alkyl) and C1-C10alkyl, or R1 and R2 are independently selected from a group including -H, C1-C-10alkyl and C3-C7-cycloalkyl, where total number of substitutes in R1 and R2 is equal to 0, 1 or 2 and substitutes are independently selected from -NH2, -NH(C1-C6-alkyl) and -N(C1-C6-alkyl) (C1-C6-alkyl); and R3 denotes C1-C10alkyl; or its enantiomer, diastereomer or mixture thereof, or its pharmaceutically acceptable salt or solvate; provided that following compounds are excluded: N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,3-propandiamine and N1,N1-dimethyl-N2-(2-phenylcyclopropyl)-1,2-ethanediamine. Invention also relates to a heterocyclic compound of formula (I'), a pharmaceutical composition based on compound of formula (I) and use of compound of formula (I).EFFECT: technical result is obtaining novel heterocyclic compounds having activity as a LSD1 inhibitor.29 cl, 7 dwg, 1 tbl, 40 ex (I) (I')

Trans-2-decenoic acid derivative and medicinal agent containing same // 2602810
FIELD: chemistry.SUBSTANCE: present invention relates to a novel trans-2-decenoic acid derivative of formula (I') or a pharmaceutically acceptable salt thereof , possessing preventive or therapeutic effect for peripheral nervous system disorders, caused by anti-cancer agents, and/or neurotrophic factor-like activity and/or analgesic action, as well as to a pharmaceutical agent based thereon.EFFECT: prevention and treatment of nervous system disorders.14 cl, 11 tbl, 56 ex

Anti-inflammatory and/or antinociceptive (z)-3-(2-oxo-2-(4-tolyl) ethylidene)piperazine-2-on, method for production thereof, pharmaceutical compositions // 2602500
FIELD: pharmaceutics.SUBSTANCE: invention relates to a drug for treating inflammatory diseases of a locomotor system, accompanied by a pain syndrome, (Z)-3-(2-oxo-2-(4-tolyl)ethylidene)piperazine-2-on of formula (I), and method for production thereof.EFFECT: treating inflammatory diseases of a locomotor system.3 cl, 2 tbl, 5 ex

ethod of detecting anticonvulsant action of sodium citicoline and valproate when applying them together on model of acute generalized convulsions caused by pentylenetetrazole in wistar male rats // 2600477
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to neurochemistry, pathophysiology, neurology and psychiatry. On the model of acute generalized convulsions, caused by pentylenetetrazole in Wistar male rats, the method of anticonvulsant action when applying sodium citicoline and sodium valproate is disclosed. Preparations are being intraperitoneally administered, at that, citicoline is being administered in a dose of 300 mg/kg one hour before the administration of pentylenetetrazole, sodium valproate is being administered in a dose of 70 mg/kg 10 minutes before the administration of pentylenetetrazole.EFFECT: selected dose schedule of the preparations provides higher anticonvulsant action also related to the neuroprotective action of preparations, which reduces the neurodegeneration in the rat brain under conditions of acute generalized convulsions caused by pentylenetetrazole.1 cl, 3 tbl

Substituted benzamide derivatives // 2595902
FIELD: chemistry.SUBSTANCE: invention relates to compound of formula (I), where R is hydrogen or C1-7alkyl; R1 represents -(CH2)n-(O)o-5-7-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, except for piperazine, where said heterocycloalkyl group optionally substituted with C1-7alkyl, hydroxy or halogen; n equals to 0, 1 or 2; o equals to 0 or 1; R2 represents CF3, C3-6-cycloalkyl, possibly substituted C1-7alkoxy or halogen, or represents indane-2-yl, or is 6-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, optionally substituted with pyrimidinyl, or is 5-6 mono- or 9-10-member bicyclic heteroaryl containing 1-2 heteroatoms selected from N, O and S, where the heteroaryl is not thiazol and where said aromatic ring, is possibly substituted with one or two substitutes selected from C1-7alkyl, halogen, 5-6-member heteroaryl containing 1-2 heteroatoms selected from N and O, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2Cl)(CH3), S-C-1-7alkyl, C1-7alkoxy, CH2-C-1-7alkoxy, C2-7alkynyl or cyano, or substituted with -C(O)-phenyl, -O-phenyl, -O-CH2-phenyl, phenyl, and where said phenyl ring may be substituted with halogen, -C(O)OH or -C(O)O-C-1-7alkyl, or said aromatic ring, is possibly substituted with 5-6-member heterocycloalkyl, containing 1-2 heteroatoms selected from N and O, OCH2-oxetane-3-yl or O-tetrahydropyran-4-yl, possibly substituted C1-7alkyl; X is bond, -CH2NH-, -CHR″-, -(CHR″)q-O-, -O-(CHR″)q- or -(CH2)2-; Y is bond; R″ is hydrogen, C1-7alkyl, CF3, C1-7alkoxy; q is equal to 0, 1, 2 or 3; or pharmaceutically acceptable acid addition salt thereof, except for compounds specified in patent claim. Invention also relates to specific compounds specified in patent claim. Compounds are intended for producing medicinal agents, showing affinity to TAAR1.EFFECT: technical result: benzamide derivatives having high affinity to receptors associated with TAAR1 trace amines.9 cl, 1 tbl, 323 ex

Solid dosage form of preparation of sedative and hypnotic effect // 2589833
FIELD: medicine.SUBSTANCE: invention relates to a solid dosage form of sedative and hypnotic effect. Said dosage form is a tablet or capsule, which contains hydroxyzine in amount of 3.33 to 4.5 wt%, ethyl ether of α-bromo-isovaleric acid in amount of 5.47 to 7 wt%, peppermint oil or mixture thereof with hop oil in amount from 0.39 to 0.48 wt%, β-cyclodextrin in amount of 37-50 wt% and additives, including combined water.EFFECT: invention is characterised by high sedative properties and hypnotic efficiency compared to existing analogues, which provides long sleep duration and faster onset thereof.3 cl, 3 tbl, 3 ex

Fatty acid fumarate derivatives and uses thereof // 2588256
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula I or pharmaceutically acceptable salts thereof, enantiomers or stereoisomers; in which values for groups W1, W2, R3, L, Z, a, b, m, c, d, etc. are defined in patent claim.EFFECT: invention also refers to pharmaceutical compositions based on said compounds possessing inhibitory activity on NF-kB, for treating inflammation or inflammatory disease, type II diabetes, insulin-resistant cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dislipidemia, retinopathy, neuropathy, macular edema, diabetic nephropathy, IgA nephropathy, CLD, inflammatory diseases of kidneys.25 cl, 4 dwg, 25 ex, 1 tbl
ethod for integrated treatment of postpartum endometritis in suture inconsistency on uterus after caesarean section by controlled negative pressure // 2587034
FIELD: medicine.SUBSTANCE: therapeutic-diagnostic laparoscopy is performed, during which sanation of small pelvis with 0.5 % chlorhexidine solution is carried out. Removing collected effusion, in front of and behind uterine space draining with silicone tubes with diameter of 8-9 mm. Under laparoscopic control hysteroscopy is carried out with washing of uterine cavity with 0.5 % chlorhexidine solution. Double-barreled silicone tube with diameter of 6 mm is passed through uterine cavity, its intrauterine part is wrapped with foam sponge, impregnated with activated carbon, tube is anchored to cervix by separate vicryl suture. Tight cap is worn on neck of uterus, 400 ml of 0.5 % solution of dioxydine at temperature +2…+4 °C is fed through tube into uterine cavity fractionally every 8 hours. Sprinkling with 400 ml of ozonised 0.9 % saline solution with simultaneous aspiration of content of cavity and continuously maintaining negative pressure in uterine cavity within range of 50-70 mm Hg using a RENASYS GO device and simultaneously through silicone tubes located in front of and behind uterine spaces, into abdominal cavity is fed ozonised saline solution in amount 400 ml twice a day with exposure of 30 minutes. Treatment is performed with underlying uterotonic, antibacterial therapy.EFFECT: method enables to localise process within lesser pelvis, creates conditions for distinction of process, keeps moist environment, stimulating angiogenesis, reinforcing fibrinolysis, promotes functioning growth factors, thereby improving blood circulation in wall of uterine cavity, considerably reduces possibility of contamination of pathological microflora in uterine wall thickness, thus reduces inflamed tissue oedema, improves contractile function of uterus, cleansing and regression of inflammatory process in endometrium and myometrium.1 cl, 1 ex

Composition of agents for detecting epithelial tumour cells and preparation method thereof // 2585114
FIELD: chemistry.SUBSTANCE: invention relates to a composition of agents for detecting living cells, in particular for epithelial tumour cells; composition contains 0-5 % folic acid, 0-10 % folic acid composite, 0.01 - 5% methylene blue, 0.1-10 % carbohydrate reducing agent, 2-6 % acetic acid and 3-95 % water.EFFECT: present invention also relates to a method of preparing a composition for detecting agents and kits containing composition of detection agents.21 cl, 1 tbl, 6 ex
ethod of treating chronic diseases based on modulation of antiviral immunity // 2582295
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to therapy, and can be used for treatment of chronic diseases, burdened herpes virus latent infection. Method involves introduction of chemopreparations and preparations of medicinal plants and physiotherapeutic exposure stimulating interstitial humoral transport and lymphatic system function. Introduction of preparations and physiotherapeutic exposure is combined with hepatotrophic agents, normalising gastric and intestinal intake of intestinal chelators, vitamins and trace elements. In addition, method includes epicentre antiviral lymphotropic therapy at Urin point with immunomodulating preparations of polyoxidonium and cycloferon.EFFECT: using present method provides higher clinical effectiveness in chronic diseases, burdened by herpetic infection by lymphotropic introduction of immunomodulator.1 cl, 2 tbl
ethod of activation of cognitive function in laboratory animals // 2578446
FIELD: medicine.SUBSTANCE: invention can be used to activate the cognitive functions in laboratory animals. For this purpose outbred laboratory mice are given drug "Polioksidony", which is added in an amount of 1 mg per day for 5 days, mixing it with food.EFFECT: use of this method allows you to activate the cognitive function in laboratory animals in order to select adequate controls in the study of mnemonic effects of drugs.1 cl, 3 ex

Substance having combined antiaggregant, anticoagulant and vasodilator activity, and method of producing n, n '-substituted piperazines // 2577039
FIELD: chemistry.SUBSTANCE: invention relates to N, N′-substituted piperazines of formula I and a method of producing compounds of formula II. Said compounds affect hemostasis system and exhibit antiplatelet, anticoagulant and vasodilatory properties. In general formula (I) R1 - linear or branched alkyl C1-C4, R2 - linear or branched alkyl C5-C12, G - mineral or organic C1-C4 acid or water, in general formula II R1 - linear or branched alkyl C1-C4, R2 - linear or branched alkyl C1-C12, G - mineral or organic C1-C4 acid or water. EFFECT: disclosed method enables to obtain compounds of formula II with purity of over 99 % and content of individual impurities not more than 1/10 % and sum of impurities of not more than 5/10 %.11 cl, 2 dwg, 6 tbl, 13 ex

Novel cyclopentane derivatives // 2572555
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed invention relates to compounds of formula where A1 and R1, R2, R3, R4 and R5 are determined in invention formula, which are preferable inhibitors of cathepsin cycteinprotease, in particular cathepsin S or L cycteinprotease, which makes them useful as medications, especially for treatment of diabetes, atherosclerosis, aneurism of abdominal aorta, peripheral arterial disease or diabetic nephropathy.EFFECT: invention relates to methods of obtaining claimed compounds, thereof-containing pharmaceutical composition and thereof application.24 cl, 1 tbl, 255 ex

Apoptosis inducing agents for treating cancer, immune and autoimmune diseases // 2568611
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds specified in a group shown below. The compounds contain at least 5 rings including a fragment with a bridge structure with a carbon side of the central group C(O)-NH-SO2, piperidinyl, or piperazinyl, or phenyl; phenyl attached to each carbon and sulphur atom of the group C(O)-NH-SO2, wherein phenyl from the sulphur atom side is substituted by a nitro group and NH-CH2(tetrahydro-2H-pyran-4-yl or cyclohexyl) group. The compounds possess the properties of Bcl-2 antiapoptotic protein activity inhibitor and can be used in treating the diseases expressing Bcl-2 protein. These diseases are malignant diseases specified in bladder cancer, cerebral cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia etc. The compounds of the present invention are specified in a group consisting of 4-(4-{acetyl[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; 4-(4-{benzoyl[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-3′-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}biphenyl-4-carboxamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-(4-{(phenylacetyl)[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)-4-(4-{2-[(1R,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-en-2-yl]benzylidene}piperidin-1-yl)benzamide; 4-[4-(2-{5-[8-azabicyclo[3.2.1]oct-8-ylmethyl]-2-thienyl}benzyl)piperazin-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-(4-{(3-phenylpropanoyl)[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-1-yl)benzamide; 4-{4-[adamantan-1-ylmethyl]piperazin-1-yl}-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; 4-(4-{2-[adamantan-1-yl]-2-oxoethyl}piperazin-1-yl)-N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)benzamide; N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulphonyl)-4-{4-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazin-1-yl}benzamide and other compounds or their therapeutically acceptable salts listed in the patent claim.EFFECT: compounds possess the properties of Bcl-2 antiapoptotic protein activity inhibitor and can be used in treating the diseases expressing Bcl-2 protein.6 cl, 1 tbl, 85 ex

ethod for correction of endothelial dysfunction with combination of rosuvastatin and thioctic acid in hypooestrogen-l-name-induced nictic oxide deficiency // 2568365
FIELD: medicine.SUBSTANCE: method involves simulating a dysfunction by performing a bilateral ovariectomy in Wistar male rats. On the 43rd postoperative days, L-nitro-arginine-methyl ester (L-NAME) is administered intragastrically in a dose of 25 mg/kg daily during 7 days. The induced dysfunction is corrected by daily intragastric administration of Rosuvastatin 0.85 mg/kg and thioctic acid 50 mg/kg during 7 days concurring with the administration of L-NAME into the rats.EFFECT: method provides activating the correction of the endothelial dysfunction in hypooestrogenemia.1 tbl, 1 ex

ethod for discovering anticonvulsant action of citicoline in pentylenetetrazole kindling model involving male c57b1/6 mice // 2567275
FIELD: medicine.SUBSTANCE: discovering process is shown in pentylenetetrazole kindling model involving male C57B1/6 mice. Action of citicoline is determined after administered in a dose of 500 mg/kg one hour before administration of pentylenetetrazole. The administration is conducted in the different regimens in different groups of animals, in particular: daily during 24 days, once on the 14th day of kindling or during 14 days of kindling.EFFECT: possibility to discover a spectrum and degree of manifestation of anticonvulsant action of the preparation.2 tbl

Therapeutic application of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine // 2564666
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine and can be used for long-term treatment of depression or anxiety for longer than 12-month period in patient who previously received drug treatment, with treatment being stopped because of undesirable side effects, associated with body weight. For this purpose 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine and/or its pharmaceutically acceptable salts are applied. Also claimed are: method of long-term treatment of depression or anxiety and application of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine and/or its pharmaceutically acceptable salts for production of medication.EFFECT: group of inventions provides reduction of side effects, associated with change of patient's body weight in long-term treatment.15 cl, 4 tbl, 2 ex

Anticancer agent involving combinations of kinase inhibitory compounds // 2560683
FIELD: medicine, pharmaceutics.SUBSTANCE: presented is a group of inventions involving an anticancer agent for combined application of a compound representing N-(2-fluor-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide or its pharmaceutically acceptable salt of formula (I), and the compound 4-[3-chlor-4-(cyclopropylamino-carbonyl)amino-phenoxy]-7-methoxy-6-quinolinecarboxamide or its pharmaceutically acceptable salt of formula (II), (versions), an anticancer pharmaceutical composition containing the compound of formula (I) and the compound of formula (II), as well as a method of treating cancer. The compound of formula (I) , the compound of formula (II) .EFFECT: excellent anticancer effect on various types of cancer as compared to using the declared compounds separately.5 cl, 5 dwg, 5 tbl

ethod of treating and preventing neurosensory deafness and noise effects in internal ear associated with in-plant noise exposure // 2554813
FIELD: medicine.SUBSTANCE: worker is exposed to therapeutic agents and physiotherapeutic procedures as a complex. The complex involves the combined administration of Preductal MB, Nicergolin and Neiromidin in the following doses: Preductal MB 35 mg 1 tablet 2 times a day per os for 14 days; Nicergolin 4 mg intramuscularly daily 2 times a day and Neiromidin 15 mg 1 time a day for 14 days. The physiotherapeutic procedures represent 10 daily 15-min procedures of aeroionotherapy and ultratonotherapy generated by an ear electrode in the course of 5 min for each ear.EFFECT: invention enables reducing the length of treatment ensured by the functional improvement of the acoustic analyser tracts with delaying the disease progression, improving the hearing function, reducing sonitus, and increasing a whisper reception threshold.1 tbl, 2 dwg

ethylhydrofumarate prodrugs, pharmaceutical compositions containing them and methods for using // 2554347
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.47 cl, 1 tbl, 54 ex

ethod for increasing motion activity at clinical stage of rehabilitation in geriatric patients with myocardial infarction, however suffered no coronary reperfusion and revascularisation // 2546410
FIELD: medicine.SUBSTANCE: establishing the diagnosis of myocardial infarction is immediately followed by prescribing trimetazidine MB, a modified-release cardiocytoprotector trimetazidine in a dose of 35 mg 2 times a day accompanied by enhancing motion activity gradually: degree Ia activity - turning to the sides; degree Ib activity - sitting for 5-10 minutes 2-3 times a day; degree IIa activity - sitting for 20 minutes, sitting meals, changing on a chair; degree IIb activity - walking along the chamber; degree IIIa activity - coming out into the corridor, unlimited sitting; degree IIIb activity - walking along the corridor, going up the stairs one level higher; degree IVa activity - going for a walk; degree IVb activity - taking 1.0-1.5km walk. The next degree is started in accordance with the patient's chronotropic response to physical exercises providing a heart rate gain to age-specific submaximal values.EFFECT: method enables providing the more effective rehabilitation of the patients by the combined use of physical exercises and drug treatment accompanied by controlling an age-specific chronotropic criterion.3 ex, 4 tbl, 1 dwg
ethod of treating inferior alveolar neuritis in filling material penetration into inferior dental canal // 2544543
FIELD: medicine.SUBSTANCE: surgical operation is preceded by administering antibacterial agents and electrical stimulation (ES) in a projection of an inferior dental foramen and a mental foramen. The electrical stimulation is ensured by Myovolna apparatus at voltage amplitude 20-30 V, current frequency 4-7 Hz, length 10 minutes in number of 10 daily procedures. That is followed by surgical removal of the filling material from the inferior dental canal. The surgical intervention is followed by administering antibacterial, immunocorrective, desensitising agents. That is combined with daily projection 10-minute exposure of an operated segment of the inferior dental canal to laser light generated by scanning laser emitter of Intradont apparatus for 12 days. The exposure is characterised by sequential scanning mode at frequency 10 Hz increased to 60 Hz for the last 2 days, at pulse laser light power 20Wt increased to 40 Wt for the last 2 days in the stochastic scanning mode.EFFECT: method provides pain syndrome and numbness reduction of the involved skin regions in the preoperative period and optimises actions aiming at postoperative blood circulation recovery in the inferior alveolar system outpatiently, as well as reducing time of rehabilitation and recovery of the patients.3 ex

Derivatives of 2-r1-4-r2-6-polynitromethyl-1,3,5-triazines, possessing antibacterial activity // 2541525
FIELD: chemistry.SUBSTANCE: invention relates to application of 2-R1-4-R2-6-polynitromethyl-1,3,5-triazines of general formula: , where n=0, X=NO2, Cl, Br, R1=R2=OR3, OAr (R3=CH3, C2H5, CH2(CH2)6CH3, CH2CH2Cl, Ar=metha-C6H4CH3), R1=OR3, OAr, R2=N(C2H5)2; n=1, X=Cl, R1=OR3, R2=NH(CH2)2NH2, N(CH2CH2)2NCH3 as compounds, which possess antibacterial activity.EFFECT: identification of compounds based on 1,3,5-triazine derivatives, which possess high antibacterial activity.3 tbl, 7 ex

Arylsulphonamide ccr3 antagonists // 2539591
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula , where: R1, R2, R3, R4, R5 and R6, each independently, denote hydrogen, halogen, cyano, nitro or C1-6alkyl; X denotes O or S; RYa denotes -C(O)R1a, -C(O)OR1a, -C(O)NR1bR1c, -C(S)NR1bR1c, -C(NNO2)NR1bR1c, -S(O)2R1a or -S(O)2NR1bR1c; under the condition that RYa is not -C(O)O-tert-butyl; and each R1a, R1b and R1c independently denotes hydrogen, C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, C6-14aryl, 5-10-member heteroaryl containing one, two or three heteroatoms selected from O, N or S, or morpholinyl; or each pair of R1b and R1c, together with the N atom to which they are bonded, independently forms morpholinyl; under the condition that the compound is not 4-(2-(3,5-dimethylphenoxy)-5-nitrophenylsulphonyl)piperazine-1-carbaldehyde; wherein each alkyl, alkenyl, aryl and 5-10-member heteroaryl, containing one, two or three heteroatoms selected from O, N or S, is optionally substituted with one or more groups, each independently selected from (a) cyano, halogen and nitro; (b) C1-6alkyl, C6-14aryl, furanyl and morpholinyl, each optionally substituted with one or more substitutes Q; (c) -C(O)Ra, -C(O)ORa, -ORa and -SRa, wherein each Q is independently selected from a group consisting of (a) cyano, halogen and nitro; (b) C1-6alkyl and C2-6alkenyl; and (c) -C(O)Re, -C(O)ORe, and -SRe; where each Re, Rf and Rg independently denotes (i) hydrogen; (ii) C1-6alkyl or C2-6alkenyl, which are suitable for modulating CCR3 activity.EFFECT: obtaining compounds which are suitable for modulating CCR3 activity.41 cl, 1 tbl, 4 ex

Naphthylacetic acids // 2539185
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to organic chemistry, namely to a compound of formula I and to their pharmaceutically acceptable salt or their ester, wherein W means C(H)2, C(H)2-C(H)2 or C(H)(CH3); X is specified in a group consisting of: (1) O, (2) N(H), (4) S, (5) S(O) and (6) S(O)2; Y means carbon or nitrogen; R1 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) methyl optionally substituted by fluorine, (4) C1-7alkoxygroup optionally substituted by fluorine, (5) cyano group and (6) C1-7alkylsulphonyl; R2 means hydrogen, fluorine, chlorine or C1-7alkoxygroup; R3 means hydrogen, fluorine, chlorine, bromine or methyl; R4 is specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl optionally substituted by fluorine, (4) C3-7cycloalkyl, and (5) ethenyl; R5 and R6 are independently from each other specified in a group consisting of: (1) hydrogen, (2) halogen, (3) C1-7alkyl, (4) cyanogroup and (5) C3-7cycloalkyl; R7 means cyano group or S(O)2-R8, wherein R8 is specified in a group consisting of: (1) C1-7alkyl, (2) C3-7cycloalkyl, (4) C1-7alkylamino group, (5) C1-7dialkylamino group, (6) lower heterocycloalkyl optionally substituted by halogen, C1-7alkyl, or C1-7alkoxycarbonyl and (7) 2-oxa-6-azaspiro[3.3]hept-6-yl, wherein lower heterocycloalkyl means a saturated or partially unsaturated non-aromatic ring fragment containing 3 to 7 atoms bound together to form a ring structure, wherein one, two or three ring atoms are heteroatoms, whereas the rest ring atoms are carbon atoms; and pharmaceutically acceptable esters represent methyl and ethyl acid esters of formula I acceptable as prodrugs. The invention also refers to a pharmaceutical composition based on the compound of formula .EFFECT: prepared are new compounds possessing the CRTH2 receptor antagonist or partial agonist activity.23 cl, 90 ex

Using compounds binding to sigma receptor ligands for treating neuropathic pain progression caused by chemotherapy // 2537226
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, and consists in using compounds that are sigma-1 receptor antagonists.EFFECT: preparing the compounds for treating or preventing neuropathic pain caused by the chemotherapy with taxane preparations with the neuropathic pain representing allodynia or hyperalgesia.8 cl, 2 tbl, 7 dwg

Compounds of n-phenyl(pyperazinyl or homopyperazinyl)benzenesulphonamide or benzenesulphonylphenyl(pyperazine or homopyperazine), suitable for treatment of diseases responding to modulation of serotonin 5-нт6 receptor // 2535200
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of organic chemistry, namely to compounds of N-phenyl(pyperazinyl or homopyperazinyl)benzenesulphonamide or benzenesulphonylphenyl(pyperazine or homopyperazine), or to their physiologically acceptable acid addition salts, described by general formulas (I) and (I'), where X is a chemical bond or a group N-R4; R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is hydrogen, C1-C3alkyl, fluorine, C1-C2alkoxy or fluorinated C1-C2alkoxy; R4 is hydrogen, C1-C4alkyl or C3-C4cycloalkyl-CH2-; R5 is hydrogen, fluorine, chlorine, C1-C2alkyl, C1-C2alkoxy or fluorinated C1-C2alkoxy; R6 is hydrogen and n is 1 or 2. The invention also relates to a pharmaceutical composition based on the compound of formula or .EFFECT: novel compounds, modulating activity of the 5HT6 receptor are obtained.35 cl, 2 tbl, 105 ex
ethod for preserving myocardium accompanying transplantation // 2535036
FIELD: medicine.SUBSTANCE: preserving the myocardium in transplantation involves perfusion and storage of the isolated heart with using a Custodiol solution at a temperature of 2-4°C. The heart tissue culture into the donor precedes a 10-12-hour infusion of Levosimendan 10 mcg/kg of body weight, while the perfusion and storage of the isolated organ is ensured by adding Levosimendan into the Custodiol solution at 10 mcg of the preparation per 1 litre of the solution. The surgical stage of the heart transplantation after the recipient's aorta de-clamping and the blood flow recovery is followed by introducing Levosimendan 12.5 mg into the continuing bypass circuit and infusing it for 1 hour.EFFECT: invention aims at preventing the ischemic and re-perfusion myocardial injuries, providing the adequate function of the donor's heart in the recipient's body.2 ex
ethod of treating chronic calculous prostatitis // 2534853
FIELD: medicine.SUBSTANCE: method involves a course of 5-7 pulse ultrasonic procedures having an intensity of 0.2-0.4 W/cm2 of 5-7 minutes daily. That is combined with enzyme therapy with Longidaza 3,000 units 2 times a week for 1 month. Besides, Trilon B rectal suppositories 1,000 mg and Dimexidum 200 mg are administered daily for the night for 3 months. The bacteria are detected by a microscopic and microbiologic examination of ejaculate that is followed by a 4-6-week antibacterial therapy by administering an antibacterial preparation taking into account the microflora sensitivity.EFFECT: such implementation of the method provides removing the prostate stones or decreasing the number thereof, reducing a probability of the inflammatory process in the prostate, ensuring a differentiated therapeutic approach by detecting the group of patients whom the antibacterial therapy is indicated to.3 cl, 3 ex

2,5-disubstituted arylsulphonamide ccr3 antagonists // 2532515
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula I, possessing a modulating action with respect to the CC chemokine receptor 3 (CCR3), a based on them pharmaceutical composition, versions of treatment methods and a method of controlling the CCR3 activity. In the general formula I R1 and R2 represent halogen or C1-6alkyl; R3 represents cyano or nitro; R4 represents or ; R5 represents oxo; C1-6alkyl, optionally substituted with halogen atoms; or C(O)OR1a; X represents O or S; Y represents -O-, -S-, -N(R1a)-, -C(R1a)(R1d)- or -C(R1a)(NR1bR1c)-; m represents an integer number from 0 to 2; n represents 1; p represents an integer number from 0 to 2; r represents 1 or 2; and each R1a, R1b, R1c and R1d represents (a) hydrogen; (b) C3-7cycloalkyl; or (c) C1-6alkyl, optionally substituted with hydroxyl, or each pair R1b and R1c together with a N atom, which they are bound to, form imidazoimidazolyl, substituted with oxo, butyl or chlorine, or heterocycle, containing 5 or 6 atoms in a cycle.EFFECT: improvement of the composition properties.41 cl, 2 tbl, 7 ex
ethod for endoscopic treatment of gastroduodenal ulcers // 2532492
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns an endoscopic treatment of gastroduodenal ulcers. The method involves conducting therapeutic endoscopy in the first phase of an ulcerous process. An insufflator is used to apply diotevine 0.05-0.3 g first on an ulcer base, and then diovine 0.1-0.5 g to cover the whole ulcer.EFFECT: method provides the more effective antiulcer therapy, reducing the length of treatment, including by the fast ulcer clearance from the necrotic tissue in a combination with the repair process stimulation.2 tbl, 1 ex

ethod of treating poultry with polycationic triviron compound // 2532355
FIELD: medicine.SUBSTANCE: method involves administering into the poultry the polycationic compound 1,5-bis-(4-tetradecyl-1,4-diazoniabicyclo[2.2.2]octan-1-yl)pentan tetrabromide dissolved in 85% formic acid with reducing the concentration to 3 gram per 1 litre of the acid; then the mother solution is diluted with tap water to the concentration of the mother solution of 10 ml per 1 litre of water, and administered orally into the poultry.EFFECT: invention provides the antiviral and antibacterial action, higher efficacy of treating and preventing the poultry's viral infections caused by viral RNAs, a possibility to administer the therapeutic solution orally through a watering system.9 cl, 1 tbl, 8 ex

Antimalarial compounds // 2530899
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formulas I, II, III, IV, V, VIII or to their pharmaceutically acceptable salts, wherein: Z represents , or phenyl; D represents or ; X represents N(R9), O, S, S(=O) or S(O)2; each Y independently represents O or S; G represents or ; the other radical values are described in the patent claim. The invention also refers to pharmaceutical compositions based on the above compounds.EFFECT: there are prepared new compounds and based compositions which can find application for treating malaria or eliminating or inhibiting the growth of Plasmodium species.30 cl, 3 tbl, 23 ex
ethod of obtaining medical form of trimetazidine of prolonged action // 2530558
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to a method of preparing a drug form of trimetazidine dihydrochloride with the modified release. According to the method modifiers of release - Kollidon SR and hydroxypropylmethylcellulose are mixed, trimetazidine dihydrochloride is added to the mixture, microcrystalline cellulose is mixed with an aerosol in a separate vessel and sifted to obtain a homogenous mass, two mixtures are mixed with each other, powdered with sliding substances, the obtained mass is pressed with the following application of a film coating Opadry II on tablet cores, with taking 10-40% of trimetazidine dihydrochloride, 10-70% of the said modifier of release, 10-80% of the said filler, 0.1-1.0 % of sliding substances and 2-6% of the said film coating of a pill weight.EFFECT: method of preparing the solid drug form of trimetazidine dihydrochloride is simple and ensures less time and labour consumption.2 tbl, 5 ex

Derivative of n-acylanthranilic acid or its salt // 2529860
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to a novel derivative of N-acylanthranilic acid, represented by the following general formula 1, or to its pharmaceutically acceptable salt, in which R1, R2, R3, X1, X2, X3, X4 and A are determined in the invention formula.EFFECT: invention relates to an inhibitor of collagen production, a medication for treating diseases, associated with the excessive production of collagen, containing N-acylanthranilic acid derivative Formula 1.

2,5-disubstituted arylsulphonamide ccr3 antagonists // 2527165
FIELD: chemistry.SUBSTANCE: invention relates to 2,5 substituted arylsulphonamides of formula (Ia) or to their pharmaceutically acceptable salts, solvates, hydrates, stereoisomers or tautomers, where X represents S, SO or SO2; Y and Z represents (i) Y represents NR5; and Z represents =O, CO2R6 or C1-6alkyl; or (ii) Y represents CH2, CHF, CHCH3, O, S or SO2; and Z represents hydrogen or C1-6alkyl; R1 and R2 each independently represents halogen, C1-6alkyl or C1-6 halogenalkyl; R3 represents CN or NO2; R4 represents hydrogen or C1-6alkyl; R5 represents hydrogen or C1-6alkyl; and R6 represents hydrogen or C1-6alkyl. Invention also relates to compounds of formula (I) and (II), values of radicals of which are given in the invention formula, specific compounds, pharmaceutical composition based on compound of formula , and , method of modulating CCR3 activity.EFFECT: obtained are novel compounds, possessing useful biological properties.18 cl, 1 tbl, 3 ex

Substituted aminoindans and analogues thereof to be used in pharmaceutics // 2522586
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.22 cl, 27 dwg, 1 tbl, 756 ex

Application of amine derivatives of fullerenes c60 and c70 and based on them compositions as antimicrobial preparations // 2522012
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the chemical-pharmaceutical industry and deals with application of fullerene derivatives of the general formula 1 , where in the general formula 1 fragment C2n stands for: fullerene carbon cage C60 (n=30), C70 (n=35); where in the general formula 1 "x" can take values from 4 to 12, and "y" from 0 to 16, where in the general formula 1 fragment A stands for a monovalent atom of fluorine or hydrogen; -oxygen atom (-O-), bound to the fullerene cage in a composition of an oxirane fragment; where in the general formula 1 NR1R2 is described by the following definitions: - amine residue, where R1 and R2 are hydrogen atoms or substituted with protonated (NH3 +) or unprotonated (NH2) aminogroups or branched alkyl radicals (CmH2m+1; m=1-20); - residue of piperazine of the general formula Ic-1 , where R, R'1, R'2 R'3 and R'4 are hydrogen atoms or linear or branched alkyl (CmH2m+1 m=1-20) radicals, as antimicrobial preparations, as well as an antimicrobial composition, including fullerene derivatives.EFFECT: invention can be used in biomedical research and in production of novel medications, intended for treatment and prevention of infectious diseases, as well as for creation of disinfection agents, intended for decontamination and sterilisation of media and surfaces contaminated with microorganisms.2 cl, 4 ex, 2 tbl, 4 dwg

Low-molecular inhibitors of n-terminus activation of androgen receptor // 2519948
FIELD: chemistry.SUBSTANCE: invention relates to low-molecular inhibitors of N-terminus activation of androgen receptors of formula B: or pharmaceutically acceptable salts thereof, where: X denotes N; Y denotes O; R1 denotes OJ, where J denotes a linear or branched, saturated C1-10alkyl; R2 denotes a linear or branched, saturated, optionally substituted C1-10alkyl, where the optional substitute denotes one or more: F, Cl, Br and I; R3 denotes H; R4 denotes H, linear or branched, saturated C1-4alkyl, optionally substituted, where the optional substitute denotes one or more: F, Cl, Br and I; R5 denotes a linear or branched, saturated C1-10alkyl, optionally substituted, where the optional substitute denotes one or more: F, Cl, Br and I; Z denotes Bu, Pr, Et or Me; denotes a double bond; and under the condition that the compound is not: .EFFECT: compound exhibits inhibiting activity on AR, which allows use thereof to treat various diseases, including prostate cancer.26 cl, 9 dwg, 2 tbl, 6 ex
ethod of predicting course of myocardial infarction basing on assessment of mitochondrial dysfunction expression // 2519700
FIELD: medicine.SUBSTANCE: claimed invention relates to medicine, in particular to cardiology, and deals with prediction of a course of myocardial infarction. For this purpose, at the background of the standard therapy in a patient with myocardial infarction carried out is measurement of the level of anaerobic cycle enzymes - succinatedehydrogenase, lactic and pyruvic acids and lipid peroxidation - malonic dialdehyde. After that, trimetazidine is introduced to the patient and after 12 hours the level of enzymes is re-measured. Reduction of their level to normal values testifies to the presence of compensatory abilities of the myocardium energy system and makes it possible to make reliable prediction of low risk of death as a result of acute myocardial infarction.EFFECT: prediction of the course of myocardial infarction.2 ex

Amyloid-binding agents // 2517174
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, having the capacity to bind amyloid peptides and/or amyloids. In formula (I), EDG is an electron donor group, πCE is a pi-coupling element and WSG is a water-soluble group. EDG is -NR4R5, where R4 and R5 independently denote hydrogen, R12-substituted or unsubstituted C1-C10alkyl, where R4 and R5 are optionally linked to form a R12-substituted or unsubstituted 6-member heterocycloalkyl, where said 6-member heterocycloalkyl optionally contains a heteroatom selected from O or N, R12 is an unsubstituted C1-C10alkyl or unsubstituted 6-member heterocycloalkyl, where said 6-member heterocycloalkyl contains a heteroatom selected from O or N. The pi-coupling element has the formula -L1-(A1)q-L2-(A2)r-L3-, in which q and r are independently equal to 0 or 1 and at least one of q and r is equal to 1, A1 and A2 denote an unsubstituted group , L1, L2 and L3 independently denote a bond or a binding group of formula , where x is an integer from 1 to 50. The water-soluble group is a R25-substituted C1-C5alkyl or group, where R25 is -OR26 or a R29-substituted 5-member heterocycloalkyl containing two O atoms, R26 is hydrogen, R29 is an unsubstituted C1-C10alkyl and y is an integer from 1 to 50.EFFECT: invention relates to specific compounds of formula (I), pharmaceutical compositions and a method of detecting an amyloid peptide.14 cl, 11 dwg, 5 tbl, 11 ex
ethod of optimisation of intellectual activity of learners // 2516117
FIELD: teaching.SUBSTANCE: learners are affected by electromagnetic radiation of extremely high frequency with the modulations of frequency range from 43 GHz to 44 GHz. Simultaneously with the electromagnetic radiation 0.2 g of caffeine is administered. This combined effect is carried out for 20 minutes in the morning hours daily as a course of 5 procedures.EFFECT: effective recovery of mental capacity, long-lasting maintenance of the results achieved, easy in performing.1 tbl

Novel compounds of reverse turn mimetics, method of their manufacturing and application // 2515983
FIELD: chemistry.SUBSTANCE: described are novel pyrazine triazinone derivatives of general formula wherein Ra represents C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkinyl; Rb represents phenyl, substituted with acyl, alkoxy, hydroxyl, nitro, NH2, thioalkyl group or -C(=O)Re, where Re is C1-C6 alkyl, or group -C(=O)Re, where Re represents C1-C6 alkyl or cyclopropyl and Rp represents -H, -PO3H2, -HPO3 -Na+, -PO3 2-Na2 +, pharmaceutical composition, containing thereof, and method of treating acute myeloleukosis.EFFECT: novel compounds represent reverse turn mimetics and can be applied in medicine.9 cl, 1 dwg, 3 tbl, 24 ex

Phenyl alkyl piperazines, which modulate tnf activity // 2512567
FIELD: chemistry.SUBSTANCE: invention relates to phenyl alkyl piperazines of formula (I) , in which: R1 represents independently on each other hydrogen atom, halogen atom, (C1-C5)alkyl group, (C1-C5)halogenalkyl group, (C1-C2)perfluoroalkyl group, (C1-C5)alkoxyl group or (C1-C2)perfluoroalkoxyl group; R2 stands for (C1-C5)alkyl group or (C1-C5)alkoxyl group, R3 represents (C1-C5)alkyl group; A represents =CH- and =N-; in form of base or additive salt with acid. Invention also relates to pharmaceutical composition for modulation of activity of TNF-alpha, which contains claimed compounds, and to method of their obtaining.EFFECT: obtained are novel compounds which can be applied in medicine as medications for treating or preventing pain and/or diseases, associated with inflammatory of immune disorders.24 cl, 3 ex

Pharmaceutical composition for reduction of primary radiation response and early transient incapability // 2509557
FIELD: medicine, pharmaceutics.SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.EFFECT: what is developed is the new composition.3 cl, 3 tbl, 2 dwg
ethod for training pelvic floor muscles in treating patients suffering erectile dysfunction following radical prostatectomy // 2499585
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically urology. A method involves the complex postoperative rehabilitation. From the 10th postoperative day, the patient is exposed to electric myostimulation at current intensity to pelvic floor muscle contraction, frequency 30-50 Hz, modulation depth 100% for 10-15 minutes. The therapeutic course is 12-20 daily procedures. In one month from the operation, the ischiocavernous and bulbospongiosus muscles are trained. That involves doing three exercises thinking of 'penis contraction'. The first exercise represents 5 tensions with maximum intensity (100%), length 5 seconds and tension pauses 90 seconds. The second exercise represents 5 tensions with intensity 50% of maximum intensity, length 15 seconds and tension pauses 20 seconds. The second exercise represents 5 tensions with intensity 30% of maximum intensity, length 30 seconds and tension pauses 20 seconds. The exercises are done min. 3 times, once a week in the morning and evening. They are added with doing the interval exercises for lower extremity muscles. The exercises include 15-minute warm-up activities and doing the exercises of intensity 70-80% of maximum intensity, 50-60% of maximum heart rate, repeated for 5 times with 3-minute pauses. The exercises are done not less than 3 times. From the second postoperative month, a phosphodiesterase-5 inhibitor is administered.EFFECT: method provides improving the quality of erection ensured by erection compression of the superficial veins of penis and blood outflow blocking from the cavernous body and prolonged therapeutic effect.4 cl, 1 ex
 
2550866.
Up!